Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Processa Pharmaceuticals, Inc. Common

PCSA

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

Last trade $1.73
Day change +$0.01 (+0.58%)
Day range $1.71 – $1.77
Volume 14,865
Market cap $5M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.81M
Price / earnings
—
Price / book
0.03×
Price / sales
—
EV / sales
—
EV / EBITDA
11.34×

Profitability

Earnings per share
-$69.03
Return on assets
-106.12%
Return on equity
-107.22%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
97.7×
Quick ratio
97.7×
Cash ratio
96.73×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.66M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PCSA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$4.29M$1.69M$1.52M$1.59M$1.83M$1.5M$1.26M$1.02M
Research and development$1.81M$649.88K$1.81M$2.11M$1.66M$2.45M$1.59M$1.71M
Total operating expenses$184.13M$2.34M$3.33M$3.7M$3.49M$3.95M$2.85M$2.73M
Operating income-$184.13M-$2.34M-$3.33M-$3.7M-$3.49M-$3.95M-$2.85M-$2.73M
Interest expense$1.01M-$2K$0$0$46K$8.86K$0$0
Income before taxes-$183.16M-$3.27M-$3.38M-$3.36M-$3.44M-$3.93M-$2.83M-$2.73M
Income taxes$0$0$0$0$0$0$0$0
Net income-$183.16M-$3.27M-$3.38M-$3.36M-$3.44M-$3.93M-$2.83M-$2.73M
Net income attributable to common shareholders-$183.16M-$3.27M-$3.38M-$3.36M-$3.44M-$3.93M-$2.83M-$2.73M
EBITDA-$6.1M-$2.34M-$3.33M-$3.7M-$3.49M-$3.95M-$2.85M-$2.73M
Basic earnings per share-$61.58-$1.19-$1.29-$1.44-$1.81-$6.26-$7.58-$19.39
Diluted earnings per share-$61.58-$1.19-$1.29-$1.44-$1.81-$6.26-$7.58-$19.39

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Processa Pharmaceuticals Announces Key Leadership Appointments

Processa Pharmaceuticals announced key leadership appointments including Gregory J. Flesher as Chief Operating Officer, Craig Coburn as EVP Head of Research, Ashley Hall as EVP Development, and Michael P. Cruse as EVP Business Operations. These appointments follow the company's July 2026 acquisition of Vidya Therapeutics and $200 million financing. The company is advancing VT-7208, a next-generation BTK inhibitor, across Phase 2 studies in food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis, with FDA clearance recently received for the CSU study.

Benzinga

Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight?

Processa Pharmaceuticals saw a significant stock price increase after initiating a Phase 2 clinical trial for next-generation capecitabine (NGC-Cap) as a potential treatment for advanced breast cancer, with interim results expected in mid-2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 17, 20251-for-25reverse split
Jan 22, 20241-for-20reverse split
Dec 23, 20191-for-7reverse split
Dec 8, 20171-for-7reverse split
Feb 17, 20041-for-5reverse split